Endometriosis is defined as the presence of endometrial-like tissue (stroma and glands) outside of the uterine cavity [1, 2]. It is estimated that 10% of women of reproductive age have endometriosis [1]. The incidence is noted to be as high as 49% in women with chronic pelvic pain [1]. The thoracic cavity is the most common location for extra abdominopelvic endometriosis [3]. The presence of endometrial tissue in the thoracic cavity is called thoracic endometriosis (TE).

Catamenial pneumothorax (CP) is the most common manifestation of TE and accounts for up to one-third of spontaneous pneumothorax occurring in women of reproductive age [4]. Other less common manifestations include hemoptysis, hemothorax, catamenial chest pain, and lung nodules.


Several hypotheses have been proposed for TE. One of the earliest and well-accepted theories is retrograde menstruation, which is defined as the spillage of viable endometrial tissue from the uterus into the pelvic cavity [2]. Anatomical asymmetry in the abdominopelvic cavity and the existence of peritoneal currents are some of the other likely explanations for the preponderance of right-sided thoracic endometriosis [2, 5]. Lymphovascular spread and transdiaphragmatic spread through congenital or acquired diaphragmatic defects are some of the other hypothesized mechanisms by which endometrial tissue could spread to the thoracic cavity [6, 7]. Another proposed theory is microembolization after trauma or uterine procedures [8, 9].

Implanted endometrium may or may not undergo cyclic hormonal changes as does normal endometrial tissue [6]. However, as learned from in vitro studies, certain growth factors like epidermal growth factor, insulin-like growth factor, and macrophage-derived growth factor may be playing a role in the proliferation of ectopic endometrial tissue, in addition to estrogen [1, 6]. Therefore, the ectopic endometrial lesions in the presence of a complex hormonal and proinflammatory environment tend to continue proliferation and angiogenesis [1].

Clinical Presentation of Thoracic Endometriosis

The clinical manifestations of TE encompass a wide spectrum of disease and patients can present with more than one clinical entity. An increasing amount of literature demonstrates non-pneumothorax-related manifestations of thoracic endometriosis (Table 1). Manifestations of TE may or may not be catamenial. The term catamenial refers to a clinical manifestation occurring around the time of menses, typically 24 h before and 72 h after the onset of menses [10].

Table 1 Clinical manifestations of thoracic endometriosis. Incidences of some of the common clinical manifestations are reported in the following table. Incidence of other rare clinical manifestations of TE not available (N/A) [11]


Pneumothorax is the most common clinical manifestation of TE accounting for 70% of cases [13]. Catamenial pneumothorax (CP) is defined as pneumothorax occurring between 1 day prior to the onset of menses and up to 3 days after the onset [4]. Less commonly, it can occur in the intermenstrual period as well [8]. Roussett-Jablosnki et al. studied pneumothorax and its temporal relationship with the menstrual cycle and described four different categories (Table 2) [8].

Table 2 Categories of spontaneous pneumothorax in women of reproductive age

Symptoms of patients presenting with spontaneous pneumothorax include cough, chest pain, and shortness of breath. Joseph et al. reported that 97.5% of cases of CP occur on the right side [9]. Roussett-Jablosnki et al. reported that up to one in every four women who presented with CP reported having a history of recurrent thoracic or scapular pain during their menstrual periods and about half of the patients reported a history of having an obstetric or gynecologic procedure [8]. History of obstetric or gynecologic procedures could add weight to the theory of microembolization leading to the vascular spread of endometriosis [8]. Ottolina et al. reported that CP is associated with pelvic endometriosis but not with infertility [14].

Catamenial Hemothorax/Hemorrhagic Pleural Effusion

Though a rare cause of pleural effusion, catamenial hemothorax composes up to 15% of all thoracic endometriosis syndromes [9]. Like CP, catamenial hemothorax also predominantly involves the right hemithorax in up to 70% of the cases with 20% occurring bilaterally [11]. However, a case series reported no laterality in catamenial hemothorax [15]. The pleural fluid analysis itself was not sufficient for establishing the diagnosis of TE in patients presenting with hemothorax or hemorrhagic effusion [16]. Joseph et al. reported the presence of pleural endometriosis and diaphragmatic defects in five out of seven patients with catamenial hemothorax who underwent VATS [9]. Recurrence rates are lower in catamenial hemothorax compared to CP [15].

For recurrent hemothorax or pleural effusion related to TE, VATS-guided wedge resection, pleurectomy, and chemical pleurodesis were reported in the literature [16, 17]. Another less invasive approach that can be considered is MT followed by diagnostic biopsies and indwelling pleural catheter placement or chemical pleurodesis.

Catamenial Hemoptysis

Catamenial hemoptysis is described as hemoptysis occurring during the menses resulting from the presence of endobronchial or parenchymal endometrial tissue [18]. Catamenial hemoptysis was noted to occur in relatively younger patients compared to the other clinical manifestations of TE [18]. Kim et al. reported that 84% of the patients with catamenial hemoptysis underwent a gynecologic procedure prior to the onset of symptoms. Imaging showed ground-glass opacities predominantly in the lower lobes further confirming the theory of microembolization of endometrial tissue [18].

Diaphragmatic Rupture

Diaphragmatic rupture can be primarily due to diaphragmatic lesions in TE or secondarily as a consequence of diaphragmatic repair for TE [10]. Bobbio et al. reported that two-thirds of women of reproductive age presenting with diaphragmatic rupture who underwent VATS were found to have endometriosis [10]. The occurrence of diaphragmatic rupture greater than 6 months after undergoing VATS for CP could be attributed to TE rather than a complication of surgery [19].

Lung Nodules

Lung nodules are not a common presentation of TE [11]. They can be present asymptomatically or identified in patients with catamenial hemoptysis [11, 18]. Lung nodules on chest computerized tomography (CT) scan can change in size and appearance depending on the temporal relation with the menstrual cycle [20].

Diagnosis of Thoracic Endometriosis

High clinical suspicion and isolation of endometrial tissue play a key role in the diagnosis of TE. The choice of clinical modality for diagnosis predominantly depends on the patient’s clinical presentation.

Radiologic Studies

Radiologic studies help determine the next step in many cases. While chest X-ray can easily detect pneumothorax and hemothorax, chest CT can be helpful in further characterizing the parenchymal lesions and presence of diaphragmatic implants which appear as hypo-attenuating areas [21]. The posterosuperior diaphragm is the most common location for the diaphragmatic implants because endometrial cells travel through the paracolic gutter and implant on the right hemi-diaphragm [21]. In contrast, the presence of phrenocolic and falciform ligaments prevent the endometrial cells from coming into contact with the left hemi-diaphragm [22]. Parenchymal endometriosis can present as single or multiple lung nodules which vary in size and characteristics in temporal relation with the menstrual cycle [20, 21]. The formation of thin-walled cavities and bullae has also been described in the literature [21].

Chest magnetic resonance imaging (MRI) may be a useful imaging modality particularly in individuals with isolated catamenial chest pain who are being considered for VATS. When performed during menses, MRI of the chest can help in identifying diaphragmatic and pleural implants when CT chest had been nondiagnostic [23, 24].

Laboratory Testing

There is no specific laboratory test to diagnose TE. Significantly higher levels of cancer antigen (CA) 125 were found in females with TE compared to those who are disease free [25]. Also, measurement of CA-125 levels can predict recurrence with high specificity and poor sensitivity [25]. A high level of CA-125 in a woman presenting with spontaneous pneumothorax could raise the suspicion of TE in the right clinical context [25].

Video-Assisted Thoracoscopic Surgery

VATS can serve as both a diagnostic and therapeutic procedure. Various findings during VATS have been described in the literature including diaphragmatic defects, diaphragmatic implants, visceral and parietal pleural implants, parenchymal implants, blebs, and bullae [11]. Although roughly half of the patients with CP who underwent VATS were found to have diaphragmatic defects, no statistical association was found between the presence of a diaphragmatic defect and the development of CP [11]. It was also noted that the odds ratio of having a hemothorax is five times higher in patients who were found to have visceral and parietal pleural implants during VATS [11]. In one case series, roughly half of the patients with CP were found to have TE [26]. The presence of the endometrial implants predominantly in the posterosuperior diaphragm might limit the ability to visualize some TE lesions during VATS [3, 21].

Medical Thoracoscopy

The utility of MT for TE is not well described in the literature. Medical thoracoscopy, or pleuroscopy, was first performed by Swedish internist, Hans-Christian Jacobaeus, over 100 years ago to help induce pneumothorax as a treatment for tuberculosis (TB) [27]. The procedure was no longer needed for TB after the advent of effective pharmacologic TB therapies in the mid-twentieth century. However, it was still practiced by pulmonologists to aid in the diagnosis of idiopathic pleural effusions [27]. MT is currently undergoing a resurgence as the field of interventional pulmonology continues to grow. The reasons for this include the procedures’ safety profile, accuracy in diagnosing malignant pleural effusions, and cost-effectiveness [28, 29]. MT differs from VATS in that it is performed by an interventional pulmonologist in a bronchoscopy suite as opposed to requiring a thoracic surgeon in the operating theater. In contrast to VATS, which requires general anesthesia with a double-lumen endotracheal tube, MT is performed through a single port with conscious sedation or monitored anesthesia care with the patient spontaneously breathing.

During the procedure, a safe location to access the pleural effusion is identified by ultrasound. Anesthesia and local anesthetic are given. The pleural space is then accessed by making a 1-cm incision followed by blunt dissection. Next, a 7-mm trocar and cannula are inserted, and the pleural fluid is aspirated and sent for analysis. With the effusion evacuated, and the patient spontaneously breathing, a pneumothorax develops. This occurs by negative pressure ventilation entraining air through the cannula into the pleural space. This allows for excellent visualization of the pleural cavity with either a rigid or semi-rigid video telescope (Fig. 1). MT allows for inspection of the parietal pleura, visceral pleura, and diaphragm. The procedure also allows the interventional pulmonologist to assess whether the lung can freely expand into the chest space versus a trapped lung or pneumothorax ex vacuo. After inspection, a separate telescope with biopsy forceps attached can be used to biopsy the parietal pleura and the diaphragm. Biopsy of the visceral pleura is deferred to avoid air leaks. Following the diagnostic portion of the procedure, a chest tube is placed to evacuate the pneumothorax. Patients are generally sent home the same day except for those patients who undergo a simultaneous talc poudrage as they require continuous chest tube drainage to achieve pleurodesis. Tunneled pleural catheters (TPCs) may also be placed during an MT to palliate suspected or known malignant pleural effusions. Overall, the MT offers the ability to diagnose, stage, and palliate malignant pleural effusions in a single outpatient procedure. However, the utility of MT in the diagnosis and treatment of TE is yet to be established.

Fig. 1
figure 1

Rigid medical thoracoscopy equipment

At our institution, we performed a diagnostic and therapeutic MT on a patient with known abdominopelvic endometriosis and recurrent hemothorax (fig. 2) suspected of having pleural endometriosis. This was performed as the patient requested a less invasive alternative to VATS. During the MT procedure, multiple pleural adhesions (Fig. 3) were taken down using biopsy forceps resulting in a partial decortication (Fig. 4). The diaphragm was inspected and free of any gross defects. The parietal pleura was biopsied confirming the presence of pleural endometriosis (Fig. 5). During the procedure, the lung was found to be trapped and not fully expanding. Therefore, a tunneled pleural catheter (TPC) was placed for the palliation of symptomatic hemothorax with trapped lung. The TPC was drained at home every other day with excellent control in symptoms. Spontaneous pleurodesis was achieved 90 days after the procedure and initiation of hormonal therapy and the TPC was removed (fig. 6). While MT with the placement of a TPC in conjunct with leuprolide hormonal therapy resulted in a good outcome, the gold standard for diagnosis and management of TE remains VATS. However, further studies on the utility of MT in the diagnosis and management of TE are probably warranted.

Fig. 2
figure 2

Chest CT showing large right pleural effusion

Fig. 3
figure 3

Pleural adhesions noted during medical thoracoscopy which were taken down resulting in a partial decortication

Fig. 4
figure 4

Inspection of visceral and parietal pleura during medical thoracoscopy showing trapped lung following partial decortication

Fig. 5
figure 5

H&E-stained section of a pleural biopsy with a focus of endometrial-type glands and stroma, diagnostic of endometriosis

Fig. 6
figure 6

Chest CT a week prior to the removal of the tunneled pleural catheter showing achievement of pleurodesis


The role of bronchoscopy in TE is limited and specific. In a case of catamenial hemoptysis, bronchoscopy with airway examination can help identify the anatomical region that is bleeding which can be followed by VATS wedge resection or endobronchial laser ablation [30,31,32]. Performing bronchoscopy during menses increases the likelihood of successfully identifying endobronchial endometrial tissue [33].

Histopathologic and Immunohistochemical Analysis

The tissue samples can be obtained by various methods as mentioned above, which includes VATS, endobronchial biopsies with bronchoscopy, and in our case pleural biopsies obtained by MT. Classic histopathologic features including the presence of endometrial glands, stroma, and hemosiderin-laden macrophages are not always present in TE making the diagnosis challenging [34]. The absence of these histopathologic findings does not rule out TE [35]. An immunohistochemical analysis positive for estrogen and progestin receptors is not always suggestive of TE as almost 60% of men with spontaneous pneumothorax were also found to be estrogen and progestin receptor positive on resected VATS specimens [34]. However, positive estrogen and progestin receptor in an aggregated pattern along with positive CD-10 could aid in the diagnosis of TE and indicate a high risk of recurrence [34].

Management of Thoracic Endometriosis

Medical Management

Anti-gonadotropic agents work by decreasing endogenous estrogen production and therefore promoting atrophy of endometrial tissue [36, 37]. Hormonal therapy alone is associated with higher recurrence after discontinuation; therefore, anti-gonadotropin agents are frequently prescribed both pre- and post-operatively [37]. Recommended duration for an anti-gonadotropin agent is at least 6 to 12 months with multidisciplinary approach and timely reassessments [4]. Some of the anti-gonadotrophic agents include cyclic or continuous oral contraceptives, dienogest, danazol, cyproterone acetate, and GnRH agonist like leuprolide [15, 38]. While there are no head to head comparison studies, one study showed that cyclic oral contraceptives had higher recurrence rates compared with continuous oral contraceptives and GnRH agonists [15]. Compared to surgical pleurodesis, hormonal treatment has higher recurrence [9].

Surgical Management

VATS remains the first line of diagnostic and therapeutic procedure for TE, especially in CP. VATS allows the surgeon to inspect and identify blebs or bullae, air leaks, signs of TE on visceral and parietal pleura, and defects in the diaphragm. Therefore, it helps in performing resection of blebs or bullae, pulmonary wedge resection, pleurectomy for lesions on parietal pleura, and diaphragmatic resection [39]. Depending on the size and location of the endometrial infiltrates, a wedge resection or segmental versus subsegmental resection or a lobectomy can be performed [40, 41]. High rates of recurrence (32% to 55%) were reported in patients with CP related to TE despite undergoing surgery followed by hormonal therapy [15, 36]. VATS performed in women with catamenial chest pain refractory to conservative management showed symptomatic improvement [10]. Pleurodesis can also be achieved by chemical pleurodesis, pleural abrasion, or parietal pleurectomy. However, patients who underwent talc pleurodesis had lower rates of recurrence compared to pleural abrasion [36].

Nezhat et al. studied four patients who had pelvic pain, chest/shoulder pain, CP, catamenial hemothorax, and history of endometriosis in varying combinations, and underwent a combination of laparoscopy for treatment of abdominopelvic endometriosis and thoracoscopy for treatment of TE [42]. This approach could potentially reduce the number of times a patient needs to undergo a procedure and provide diagnostic and therapeutic value to both abdominopelvic and thoracic endometriosis at once.


The clinical presentation of TE is broad and diagnosis can be challenging. High clinical suspicion and thorough gynecological history are paramount to establishing a diagnosis. VATS remains the gold standard for diagnosis and treatment. Hormonal treatment can be used as an adjuvant to surgical treatment. However, treating solely with anti-gonadotropic agents has higher likelihood of recurrence. Though not well described in the literature, MT could be helpful in diagnosis and management of TE-related hemothorax. We describe our experience in which MT with placement of a TPC followed by leuprolide therapy not only helped in diagnosis of TE and but also achieved spontaneous pleurodesis therefore preventing the recurrence of a hemorrhagic effusion. A multidisciplinary approach involving gynecologist, thoracic surgeon, radiologist, pulmonologist, and interventional pulmonologist is crucial to properly navigating workup and management of this complex disease process.